450
Articles
27.9K
Citations
4.4
avg. Impact Factor
62
h-index

Most Cited Articles of Baylor University Medical Center in 2014

TitleJournalYearCitations
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature20141.8K
Idelalisib and rituximab in relapsed chronic lymphocytic leukemiaNew England Journal of Medicine20141.3K
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancerBreast Cancer Research and Treatment201440
Inhibition of Pd-L1 By Mpdl3280A Leads to Clinical Activity in Pts with Metastatic Urothelial Bladder Cancer (Ubc)Annals of Oncology201413
Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastasesJournal of Oncology Pharmacy Practice201412
A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to AaAnnals of Oncology20142
Drug-induced apoptosis in mesothelioma cells from chemotherapy-naive versus patients receiving prior chemotherapy.Journal of Clinical Oncology2014
Tumor heterogeneity revealed by drug-induced apoptosis (MiCK) assays in lung cancer.Journal of Clinical Oncology2014
Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from 2 phase 2, multicenter, single-arm studies.Journal of Clinical Oncology2014